Apart from some exceptions where the issue is predetermined (Takeover bids, 4c, profit guidance, etc), the company makes the primary determination and marks the announcement as price sensitive or not - as shown below.
The ASX can however alter this: In their FAQs; Q9 & Q10:
Q9: What if I indicate the announcement is ‘market sensitive’ and ASX releases the announcement as ‘nonsensitive’?
Q10: What if I indicate the announcement is not ‘market sensitive’ and ASX releases the announcement as ‘market sensitive’?
Answer (from the ASX): "The information provided by a listed entity is an indication only. ASX will make the final determination on the market sensitivity of the submitted announcement. ... Listed entities that repeatedly do this may be contacted by ASX to discuss the reasons for this.."
https://www.asxonline.com/static/companies/files/listings/asx-market-announcements-faq.pdf
- Forums
- ASX - By Stock
- CU6
- Ann: CMS final rule on radio-diagnostic reimbursement policy
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
5.44%
!
$2.52

Ann: CMS final rule on radio-diagnostic reimbursement policy, page-15
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.52 |
Change
0.130(5.44%) |
Mkt cap ! $810.1M |
Open | High | Low | Value | Volume |
$2.39 | $2.54 | $2.37 | $5.141M | 2.072M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6820 | $2.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.52 | 3500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 405 | 2.500 |
1 | 20000 | 2.480 |
4 | 41204 | 2.450 |
1 | 5000 | 2.410 |
5 | 3695 | 2.400 |
Price($) | Vol. | No. |
---|---|---|
2.520 | 3500 | 1 |
2.540 | 37102 | 3 |
2.550 | 30520 | 6 |
2.580 | 30000 | 2 |
2.590 | 10004 | 2 |
Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online